迈威（上海）生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911 2025-11-25 22:00
Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring 2025-11-11 22:00
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress 2025-10-15 00:00
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA 2025-10-14 20:00
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders 2025-09-17 20:00
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA 2025-08-19 22:00
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs 2025-08-12 22:00
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA 2025-08-01 22:00
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection 2025-06-27 22:00
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO 2025-06-05 22:00
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG) 2025-05-30 22:00
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting 2025-05-23 22:00
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting 2025-04-30 20:00
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO 2025-04-24 20:00
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor 2025-04-02 22:00
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting 2025-03-26 20:00
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA 2024-11-14 22:00
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference 2024-11-08 22:00
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor 2024-08-26 22:00
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer 2024-08-23 22:00
1 2 3